PD-1 Inhibitors in Recurrent or Metastatic Oral Squamous Cell Carcinoma: Clinical Evidence, Patient Selection, and Immune-Related Toxicities. J Oral Health Dent Ther 2026, 1 (1), 27-31. https://doi.org/10.68041/johdt.v1i1/06.